Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Swinnen, Lode J; O'Neill, Anne; Imus, Philip H; Gujar, Sachin; Schiff, David; Kleinberg, Lawrence R; Advani, Ranjana H; Dunbar, Erin M; Moore, Dennis; Grossman, Stuart A

Swinnen, Lode J; O'Neill, Anne; Imus, Philip H; Gujar, Sachin; Schiff, David; Kleinberg, Lawrence R; Advani, Ranjana H; Dunbar, Erin M; Moore, Dennis; Grossman, Stuart A.

Afiliação

Swinnen LJ; Johns Hopkins University, Baltimore, Maryland, USA.
O'Neill A; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Imus PH; Johns Hopkins University, Baltimore, Maryland, USA.
Gujar S; Johns Hopkins University, Baltimore, Maryland, USA.
Schiff D; University of Virginia, Charlottesville, Virginia, USA.
Kleinberg LR; Johns Hopkins University, Baltimore, Maryland, USA.
Advani RH; Stanford Cancer Institute, Stanford, California, USA.
Dunbar EM; University of Florida, Gainesville, Florida, USA.
Moore D; Wichita NCORP, Wichita, Kansas, USA.
Grossman SA; Johns Hopkins University, Baltimore, Maryland, USA.

Oncotarget ; 9(1): 766-773, 2018 Jan 02.

Article em En | MEDLINE | ID: mdl-29416652

Palavras-chave

PCNSL; blood-brain barrier; high-dose methotrexate; primary CNS lymphoma; rituximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google